1、PRESSRELEASEAbbVieReportsSecond-Quarter2025FinancialResultsReportsSecond-QuarterDilutedEPSof$0.52onaGAAPBasis,aDecreaseof32.5Percent;AdjustedDilutedEPSof$2.97,anIncreaseof12.1Percent;TheseResultsIncludeanUnfavorableImpactof$0.42PerShareRelatedtoAcquiredIPR&DandMilestonesExpenseDeliversSecond-Quarter
2、NetRevenuesof$15.423Billion,anIncreaseof6.6PercentonaReportedBasisor6.5PercentonanOperationalBasisSecond-QuarterGlobalNetRevenuesfromtheImmunologyPortfolioWere$7.631Billion,anIncreaseof9.5PercentonaReportedBasis,or9.2PercentonanOperationalBasis;GlobalSkyriziNetRevenuesWere$4.423Billion;GlobalRinvoqN
3、etRevenuesWere$2.028Billion;GlobalHumiraNetRevenuesWere$1.180BillionSecond-QuarterGlobalNetRevenuesfromtheNeurosciencePortfolioWere$2.683Billion,anIncreaseof24.2PercentonaReportedBasis,or24.0PercentonanOperationalBasis;GlobalVraylarNetRevenuesWere$900Million;GlobalBotoxTherapeuticNetRevenuesWere$928
4、Million;CombinedGlobalUbrelvyandQuliptaNetRevenuesWere$605MillionSecond-QuarterGlobalNetRevenuesfromtheOncologyPortfolioWere$1.676Billion,anIncreaseof2.6PercentonaReportedBasis,or2.4PercentonanOperationalBasis;GlobalImbruvicaNetRevenuesWere$754Million;GlobalVenclextaNetRevenuesWere$691Million;Global
5、ElahereNetRevenuesWere$159MillionSecond-QuarterGlobalNetRevenuesfromtheAestheticsPortfolioWere$1.279Billion,aDecreaseof8.1PercentonaReportedBasis,or8.0PercentonanOperationalBasis;GlobalBotoxCosmeticNetRevenuesWere$692Million;GlobalJuvedermNetRevenuesWere$260MillionRaises2025AdjustedDilutedEPSGuidanc
6、eRangefrom$11.67-$11.87to$11.88-$12.08,whichIncludesanUnfavorableImpactof$0.55PerShareRelatedtoAcquiredIPR&DandMilestonesExpenseIncurredYear-To-DateThroughtheSecondQuarter2025NORTHCHICAGO,Ill.,July31,2025AbbVie(NYSE:ABBV)announcedfinancialresultsforthesecondquarterendedJune30,2025.AbbViedeliveredano